## Listing and Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1-8. (Cancelled)
- 9. (Withdrawn; currently amended) A method of killing cancer cells having a p53 mutation, said method comprising the separate, sequential or simultaneous administration to said cells of a therapeutically effective amount of a) a specific binding member an antibody or fragment thereof which binds to a the cell death receptor FAS or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, wherein said chemotherapeutic agent is a topoisomerase I inhibitor or pemetrexed.
- 10. (Withdrawn; currently amended) A method of treating cancer cells having a p53 mutation comprising the separate, sequential or simultaneous administration to a mammal in need thereof of a therapeutically effective amount of a) a specific binding member an antibody or fragment thereof which binds to a the cell death receptor FAS or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, wherein said chemotherapeutic agent is a topoisomerase I inhibitor or pemetrexed.
- 11. (Withdrawn) The method according to claim 9 wherein the cancer is one or more of colorectal, breast, ovarian, cervical, gastric, lung, liver, skin and myeloid cancer.
- 12. (Cancelled).
- 13. (Cancelled).
- 14. (Withdrawn; currently amended) The method according claim 9 wherein the <u>antibody</u> binding member is the anti-FAS antibody CH11.
- 15. (Canceled).

PHIP/ 725559.1

- 16. (Withdrawn) The method according to claim 9 wherein said chemotherapeutic agent is irinotecan (CPT-11).
- 17. (Withdrawn; currently amended) The method according to claim 16 wherein said antibody or fragment thereof specific binding member and chemotherapeutic agent are provided in concentrations sufficient to produce an RI of greater than 1.5
- 18. (Currently amended) A product comprising a) a specific binding member an antibody or fragment thereof which binds to a the cell death receptor FAS or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, for the simultaneous, separate or sequential administration of said antibody or fragment thereof specific binding member and said chemotherapeutic agent in the treatment of cancer, wherein said chemotherapeutic agent is a topoisomerase I inhibitor or pemetrexed, and wherein the cancer cells comprise a p53 mutation.
- 19. (Currently amended) A pharmaceutical composition for the treatment of cancer characterised by the presence of a p53 mutation, wherein the composition comprises a) a specific binding member an antibody or fragment thereof which binds to a the cell death receptor FAS or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, wherein said chemotherapeutic agent is a topoisomerase I inhibitor or pemetrexed and (c) a pharmaceutically acceptable excipient, diluent or carrier.

- 20. (Previously presented) The product according to claim 18 wherein the cancer is one or more of colorectal, breast, ovarian, cervical, gastric, lung, liver, skin and myeloid cancer.
- 21. (Canceled)
- 22. (Canceled)
- 23. (Currently amended) The product according to claim 18 wherein the antibody binding member is the anti-FAS antibody CH11.
- 24. (Canceled).
- 25. (Currently amended) The product according to claim <u>18</u> wherein said chemotherapeutic agent is irinotecan (CPT-11).
- 26. (Currently amended) The product according to claim 25 wherein said <u>antibody or fragment thereof specific binding member</u> and chemotherapeutic agent are provided in concentrations sufficient to produce an RI of greater than 1.5.
- 27. (Currently amended) A kit for the treatment of a cancer characterised by the presence of a p53 mutation, said kit comprising a) a specific binding member an antibody or fragment thereof which binds to a the cell death receptor FAS or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, wherein said chemotherapeutic agent is a topoisomerase I inhibitor or pemetrexed and (c) instructions for the administration of (a) and (b) separately, sequentially or simultaneously.
- 28. (Previously presented) The pharmaceutical composition according to claim 19 wherein the cancer is one or more of colorectal, breast, ovarian, cervical, gastric, lung, liver, skin and myeloid cancer.

PHIP/ 725559.1

- 29. (Canceled)
- 30. (Canceled)
- 31. (Currently amended) The pharmaceutical composition according to claim 19 wherein the antibody binding-member is the anti-FAS antibody CH11.
- 32. (Canceled).
- 33. (Previously presented) The pharmaceutical composition according to claim 19 wherein said chemotherapeutic agent is irinotecan (CPT-11).
- 34. (Currently amended) The pharmaceutical composition according to claim 25 wherein said specific binding member antibody or fragment thereof specific binding member and chemotherapeutic agent are provided in concentrations sufficient to produce an RI of greater than 1.5.